Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.

NCT07658378 — Phase 4, Not yet recruiting, 100 participants, Helwan University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT07658378
Status	Not yet recruiting
Phase	Phase 4
Study type	Interventional; randomized, parallel, masking: single, prevention
Enrollment	100 (Estimated)
Sponsor	Helwan University (Other)
Conditions	Surgical Site Infection (SSI)
Interventions	Cefazolin 2 g Infusion, Cefazolin 2 GM Injection (Drug)
Dates	start 2026-07-01 (estimated), primary completion 2026-09-30 (estimated), completion 2026-12-31 (estimated), first posted 2026-06-22, last updated 2026-06-24

-Summary

A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.

Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Intraoperative continuous infusion (CI) of cefazolin	Experimental	Drug: Cefazolin 2 g Infusion
Intermittent (INT) cefazolin	Active comparator	Drug: Cefazolin 2 GM Injection

Cefazolin 2 g Infusion (Drug): To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.
Cefazolin 2 GM Injection (Drug): To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

+Outcome measures

Primary outcomes

Incidence of SSI [Within 3 months after surgery]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Cardiothoracic ICU-admitted patients who underwent CABG on CPB.

Exclusion Criteria:

* Patients who require reoperation within 30 days.
* Immunosuppressant patients.
* Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
* Pregnancy or breastfeeding.
* Patients who refused to sign the informed consent.